GlassScriptPhysician profile
Garrett L Jones
NPI 1760865216
$2,612.23
in general payments reported to CMS, 2019-2025
18 companies · $717 in 2025
The $717 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $548 · 2023: $523 · 2024: $585 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $738.47 | 2021-2025 | |
| Lundbeck LLC | $363.26 | 2022-2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.00 | 2023-2025 | Relistor |
| Valinor Pharma, LLC | $273.07 | 2023-2025 | Movantik |
| Amgen INC. | $160.22 | 2021-2022 | |
| Pfizer INC. | $139.31 | 2023-2025 | |
| Lilly USA, LLC | $128.84 | 2021-2024 | Emgality, Reyvow |
| Upsher-Smith Laboratories LLC | $116.71 | 2021-2022 | |
| Ibsa Pharma INC. | $68.98 | 2023-2024 | Tirosint, Licart, Tirosint |
| Abbott Laboratories | $67.75 | 2024-2025 | Eterna |
| Teva Pharmaceuticals USA, INC. | $60.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $57.96 | 2021 | |
| Collegium Pharmaceutical, INC. | $54.85 | 2022 | |
| Supernus Pharmaceuticals, INC. | $40.06 | 2022 | |
| Forte Bio-Pharma LLC | $19.79 | 2025 | Prolate, Tanlor, Nalocet |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $18.72 | 2025 | Symbravo |
| Biodelivery Sciences International, INC. | $17.23 | 2021 | |
| Redhill Biopharma INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.